A Case of Multiple Myeloma Treated with Peritoneal Dialysis over a Long Period of Time

Introduction. Immunocompromised patients, such as those with multiple myeloma on peritoneal dialysis, are particularly susceptible to the occurrence of peritonitis. Case report. We presented a 56-year-old female patient with a 10-year history of multiple myeloma. The patient was on peritoneal dialysis since 2010. During 2012 the patient had the first episode of peritonitis that was successfully managed, but in 2013 the second episode of peritonitis occured. Analysis of dialysate culture and exit site swab revealed the presence of multiresistant Acinetobacter spp., which was susceptible only to colistin. Prompt colistin therapy was administered at the doses of 100,000 units/day during six days, which resulted in complete recovery of the patient, as well as improvement of local abdominal findings. Gram-negative bacteria (genus Acinetobacter) are common causative agents in hospital-acquired infections. Studies confirmed susceptibility of Acinetobacter to colistin, which was also the case with the presented patient. Intravenous administration of colistin resulted in a complete remission of this severe, life-threatening peritonitis. Conclusion. Patients with multiple myeloma and renal failure are highly prone to severe life-threatening infections.

Download Full-text

Solitary plasmocytoma of the skull: case report and review of the literature

Romanian Neurosurgery ◽

10.1515/romneu-2016-0064 ◽

2016 ◽

Vol 30 (3) ◽

pp. 412-418

Author(s):

Luis Rafael Moscote-Salazar ◽

Hernando Raphael Alvis-Miranda ◽

Willem Guillermo Calderon-Miranda ◽

Zenen Antonio Carmona Meza ◽

Nidia Escobar Hernandez ◽

...

Keyword(s):

Multiple Myeloma ◽

Case Report ◽

Rare Case ◽

Plasma Cells ◽

Age Of Onset ◽

Reticuloendothelial System ◽

Solitary Plasmacytoma ◽

Review Of The Literature ◽

Long Period ◽

Extramedullary Plasmocytoma

Abstract Solitary plasmacytoma and extramedullary plasmocytoma are tumors of malignant character composed of plasma cells, with a mean age of onset at 60 years. They can appear anywhere where the reticuloendothelial system is present. Usually these tumors lead to the development of multiple myeloma in a period of time ranging from 3 to 5 years. We present a rare case handled in our neurosurgery service associated with an unusually long period of evolution.

Download Full-text

The Role of Continuous Ambulatory Peritoneal Dialysis in End-Stage Renal Failure Due to Multiple Myeloma

American Journal of Kidney Diseases ◽

10.1016/s0272-6386(12)81021-3 ◽

1990 ◽

Vol 16 (3) ◽

pp. 216-223 ◽

Cited By ~ 25

Author(s):

Asher Korzets ◽

Frederick Tam ◽

Gavin Russell ◽

John Feehally ◽

John Walls

Keyword(s):

Multiple Myeloma ◽

Renal Failure ◽

Peritoneal Dialysis ◽

Continuous Ambulatory Peritoneal Dialysis ◽

End Stage Renal Failure ◽

End Stage

Download Full-text

Endstage Renal Failure due to Multiple Myeloma — Poor Survival on Peritoneal Dialysis

The International Journal of Artificial Organs ◽

10.1177/039139888801100109 ◽

1988 ◽

Vol 11 (1) ◽

pp. 39-42 ◽

Cited By ~ 11

Author(s):

J.S. Tapson ◽

H. Mansy ◽

R. Wilkinson

Keyword(s):

Multiple Myeloma ◽

Renal Failure ◽

Peritoneal Dialysis ◽

Tumour Cell ◽

Cell Mass ◽

Chronic Peritoneal Dialysis ◽

Poor Survival ◽

Endstage Renal Failure ◽

Dialysis Complications

This report describes five subjects with endstage renal failure due to multiple myeloma. All of the patients died within seven months of commencing chronic peritoneal dialysis. Complications were frequent during the dialysis period. Our experience supports the opinion that patients with multiple myeloma and a high tumour cell mass should not be offered dialysis.

Download Full-text

Continuous Ambulatory Peritoneal Dialysis in End-Stage Renal Disease Due to Multiple Myeloma

Peritoneal Dialysis International ◽

10.1177/089686089501506s15 ◽

1995 ◽

Vol 15 (6_suppl) ◽

pp. 236-240 ◽

Cited By ~ 7

Author(s):

Anupkumar Shetty ◽

Dimitrios G. Oreopoulos

Keyword(s):

Quality Of Life ◽

Multiple Myeloma ◽

Peritoneal Dialysis ◽

Renal Disease ◽

Continuous Ambulatory Peritoneal Dialysis ◽

Endstage Renal Disease ◽

Human Erythropoietin ◽

Tertiary Teaching ◽

The Mean

Objective To evaluate (1) the disease course, (2) the response to recombinant human erythropoietin (rHuEPO), and (3) the morbidity and mortality of patients with endstage renal disease (ESRO) dueto multiple myeloma (MM) who were treated with continuous ambulatory peritoneal dialysis (CAPO). Design Retrospective study. Setting Tertiary teaching hospital -The Toronto Hospital, Toronto, Ontario, Canada. Patients Seven patients with ESRO due to MM who were treated with CAPO. Results Mean age of the patients was 77.2 years (median 80 years, range 65 88 years). Two were in stage IB, 1 was in stage IIB, and the remaining 4 were in stage IIIB, according to Ourie and Salmon's staging. Three patients received rHuEPO; 2 of these also were receiving chemotherapy for myeloma. The mean rHuEPO requirement was 277 U/kglwk, which was more than other ESRO patients’ requirements. Mean duration of CAPO was 20.6 months (6 -58 months). The peritonitis rate was one episode in 14.4 months. The frequency of hospitalization was once in 5.6 months, and the mean number of days spent in hospital was 20 days per year. Quality of life did not get worse and, if anything, improved marginally while they were on CAPO. Three patients died after a mean survival of 32.7 months, and the remaining 4 patients are still alive. Conclusions Myeloma patients with ESRO do fairly well on CAPO without deterioration in their quality of life and with an acceptable peritonitis rate.

Download Full-text

Continuous Ambulatory Peritoneal Dialysis in End-Stage Renal Disease Due to Multiple Myeloma

Peritoneal Dialysis International ◽

10.1177/089686089501500301 ◽

1995 ◽

Vol 15 (3) ◽

pp. 236-240 ◽

Cited By ~ 2

Author(s):

Anupkumar Shetty ◽

Dimitrios G. Oreopoulos

Keyword(s):

Quality Of Life ◽

Multiple Myeloma ◽

Peritoneal Dialysis ◽

Renal Disease ◽

Continuous Ambulatory Peritoneal Dialysis ◽

Endstage Renal Disease ◽

Human Erythropoietin ◽

Tertiary Teaching ◽

The Mean

Objective To evaluate (1) the disease course, (2) the response to recombinant human erythropoietin (rHuEPO), and (3) the morbidity and mortality of patients with endstage renal disease (ESRO) due to multiple myeloma (MM) who were treated with continuous ambulatory peritoneal dialysis (CAPO). Design Retrospective study. Setting Tertiary teaching hospital -The Toronto Hospital, Toronto, Ontario, Canada. Patients Seven patients with ESRO due to MM who were treated with CAPO. Results Mean age of the patients was 77.2 years (median 80 years, range 65 88 years). Two were in stage IB, 1 was in stage lIB, and the remaining 4 were in stage IIIB, according to Ourie and Salmon's staging. Three patients received rHuEPO; 2 of these also were receiving chemotherapy for myeloma. The mean rHuEPO requirement was 277 U/kglwk, which was more than other ESRO patients’ requirements. Mean duration of CAPO was 20.6 months (6 –58 months). The peritonitis rate was one episode in 14.4 months. The frequency of hospitalization was once in 5.6 months, and the mean number of days spent in hospital was 20 days per year. Quality of life did not get worse and, if anything, improved marginally while they were on CAPO. Three patients died after a mean survival of 32.7 months, and the remaining 4 patients are still alive. Conclusions Myeloma patients with ESRO do fairly well on CAPO without deterioration in their quality of life and with an acceptable peritonitis rate.

Download Full-text

Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016

Scientific Reports ◽

10.1038/s41598-021-96804-8 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Kari Hemminki ◽

Asta Försti ◽

Markus Hansson

Keyword(s):

Multiple Myeloma ◽

Survival Data ◽

First Year ◽

Old Patients ◽

Cancer Data ◽

Survival Gain ◽

Long Period ◽

The Past ◽

Future Challenges ◽

The Difference

AbstractSurvival in multiple myeloma (MM) has developed favorably over the past decades for reasons that have been ascribed to new medications and treatment. However, development of survival over a long period and comparison to other hematopoietic neoplasms (HN) is less well known. Here we used Swedish cancer data from the Nordcan database, spanning a 50-year period from 1967 to 2016, and analyzed 1- and 5-year survival data. As a novel type of analysis we calculate the difference in survival between year 1 and 5 which indicates how well survival was maintained in the 4-year period following year 1 after diagnosis. The relative 1- and 5- year survival increased constantly; the 5-year survival graph for women was almost linear. The difference between 1- and 5-year survival revealed that the 5-year survival gain was entirely due to the improvement in 1-year survival, except for the last period. Survival improvement in all HNs exceeded that in MM. The linear 5-year survival increase for female MM patients suggests a contribution by many small improvements in the first year care rather than single major events. The future challenges are to push the gains past year 1 and to extend them to old patients.

Download Full-text